210 related articles for article (PubMed ID: 10383540)
1. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
Carlile DJ; Hakooz N; Bayliss MK; Houston JB
Br J Clin Pharmacol; 1999 Jun; 47(6):625-35. PubMed ID: 10383540
[TBL] [Abstract][Full Text] [Related]
2. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
Tang C; Shou M; Rodrigues AD
Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
5. Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO; Rees DL; Valente L; Veronese ME; Birkett DJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1076-81. PubMed ID: 7891318
[TBL] [Abstract][Full Text] [Related]
6. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
Wang JS; Wen X; Backman JT; Neuvonen PJ
J Pharmacol Exp Ther; 2002 Jul; 302(1):43-9. PubMed ID: 12065698
[TBL] [Abstract][Full Text] [Related]
7. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
Palamanda J; Feng WW; Lin CC; Nomeir AA
Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.
Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ
Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonamides on hepatic cytochrome P4502C activity in vitro, and correlation with some molecular descriptors in the dwarf goat (Caprus hircus aegagrus).
Zweers-Zeilmaker WM; Horbach GJ; Witkamp RF
Xenobiotica; 1997 Aug; 27(8):769-80. PubMed ID: 9293615
[TBL] [Abstract][Full Text] [Related]
11. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
13. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo.
Tassaneeyakul W; Birkett DJ; Pass MC; Miners JO
Br J Clin Pharmacol; 1996 Dec; 42(6):774-8. PubMed ID: 8971435
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Nelson MH; Birnbaum AK; Remmel RP
Epilepsy Res; 2001 Apr; 44(1):71-82. PubMed ID: 11255075
[TBL] [Abstract][Full Text] [Related]
15. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Baldwin SJ; Clarke SE; Chenery RJ
Br J Clin Pharmacol; 1999 Sep; 48(3):424-32. PubMed ID: 10510156
[TBL] [Abstract][Full Text] [Related]
17. Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations.
Weaver RJ; Dickins M; Burke MD
Biochem Pharmacol; 1995 Mar; 49(7):997-1004. PubMed ID: 7741772
[TBL] [Abstract][Full Text] [Related]
18. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9.
Miners JO; Birkett DJ
Methods Enzymol; 1996; 272():139-45. PubMed ID: 8791771
[No Abstract] [Full Text] [Related]
19. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
Ashforth EI; Carlile DJ; Chenery R; Houston JB
J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
[TBL] [Abstract][Full Text] [Related]
20. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.
Crewe HK; Barter ZE; Yeo KR; Rostami-Hodjegan A
Biopharm Drug Dispos; 2011 Sep; 32(6):303-18. PubMed ID: 21725985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
